Drug-eluting vs bare-metal stents in primary angioplasty: A pooled patient-level meta-analysis of randomized trials

Archives of Internal Medicine

Volumn 172, Issue 8, 2012, Pages 611-621

  De Luca, Giuseppe ^a   Dirksen, Maurits T ^b   Spaulding, Christian ^c   Kelbæk, Henning ^d   Schalij, Martin ^e   Thuesen, Leif ^f   Van Der Hoeven, Bas ^e   Vink, Marteen A ^b   Kaiser, Christoph ^g   Musto, Carmine ^h   Chechi, Tania ⁱ   Spaziani, Gaia ⁱ   Díaz De La Llera, Luis Salvador ^j   Pasceri, Vincenzo ^k   Di Lorenzo, Emilio ^l   Violini, Roberto ^h   Cortese, Giuliana ^m   Suryapranata, Harry ⁿ   Stone, Gregg W ^o  

^a MAGGIORE DELLA CARITÀ HOSPITAL   (Italy)

^b ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^c HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^d Rigshospitalet   (Denmark)

^e LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^f AARHUS UNIVERSITY HOSPITAL   (Denmark)

^g UNIVERSITY HOSPITAL BASEL   (Switzerland)

^h SAN CAMILLO FORLANINI HOSPITAL   (Italy)

ⁱ SANTA MARIA ANNUNZIATA HOSPITAL   (Italy)

^j HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^k SAN FILIPPO NERI HOSPITAL   (Italy)

^l Division of Cardiology   (Italy)

^m UNIVERSITY OF COPENHAGEN   (Denmark)

ⁿ RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^o NewYork Presbyterian Hospital   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; PACLITAXEL; RAPAMYCIN;

ANTICOAGULANT THERAPY; BARE METAL STENT; CLINICAL EFFECTIVENESS; COMPARATIVE EFFECTIVENESS; DRUG EFFICACY; DRUG ELUTING STENT; FOLLOW UP; HEART REINFARCTION; HUMAN; MEDLINE; META ANALYSIS; MORTALITY; PATIENT SAFETY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; STENT THROMBOSIS; SYSTEMATIC REVIEW;

EID: 84860372502     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.758     Document Type: Review

References (62)

1. Zijlstra F, Hoorntje JC, de Boer MJ, et al. Longterm benefit of primary angioplasty as compared with thrombolytic therapy for acute myocardial infarction. N Engl J Med. 1999;341(19):1413-1419. (Pubitemid 29513456)
2. Keeley EC, Boura JA, Grines CL. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet. 2003;361(9351):13-20. (Pubitemid 36050955)
3. Bhatt DL, Bertrand ME, Berger PB, et al. Metaanalysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39(1):9-14. (Pubitemid 34059855)
4. De Luca G, Suryapranata H, Stone GW, et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: ameta-analysis of randomized trials. JAMA. 2005;293(14):1759-1765.
5. De Luca G, Gibson CM, Bellandi F, et al. Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis. Heart. 2008;94(12):1548-1558.
6. Stone GW, Witzenbichler B, Guagliumi G, et al HORIZONS-AMI Trial Investigators. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from amulticentre, randomised controlled trial. Lancet. 2011;377(9784):2193-2204.
7. Stone GW, Grines CL, Cox DA, et al Controlled Abciximab and Device Investigation to Lower Late Angioplasty Complications (CADILLAC) Investigators. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med. 2002;346(13):957-966. (Pubitemid 34983245)
8. Suryapranata H, De Luca G, van 't Hof AW, et al. Is routine stenting for acute myocardial infarction superior to balloon angioplasty? a randomised comparison in a large cohort of unselected patients. Heart. 2005;91(5):641-645. (Pubitemid 40559358)
9. De Luca G, Suryapranata H, Stone GW, et al. Coronary stenting versus balloon angioplasty for acute myocardial infarction: a meta-regression analysis of randomized trials. Int J Cardiol. 2008;126(1):37-44. (Pubitemid 351509626)
10. Moses JW, Leon MB, Popma JJ, et al SIRIUS Investigators. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349(14):1315-1323. (Pubitemid 37186209)
11. Stone GW, Ellis SG, Cox DA, et al TAXUS-IV Investigators. A polymer-based, paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med. 2004;350(3):221-231. (Pubitemid 38067635)
12. Ardissino D, Cavallini C, Bramucci E, et al SESSMART Investigators. Sirolimus-eluting vs uncoated stents for prevention of restenosis in small coronary arteries: a randomized trial. JAMA. 2004;292(22):2727-2734. (Pubitemid 39628251)
13. Colombo A, Moses JW, Morice MC, et al. Randomized study to evaluate sirolimus-eluting stents implanted at coronary bifurcation lesions. Circulation. 2004;109(10):1244-1249. (Pubitemid 38372783)
14. Roiron C, Sanchez P, Bouzamondo A, Lechat P, Montalescot G. Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart. 2006;92(5):641-649.
15. De Luca G, Stone GW, Suryapranata H, et al. Efficacy and safety of drug-eluting stents in ST-segment elevation myocardial infarction: a metaanalysis of randomized trials. Int J Cardiol. 2009;133(2):213-222.
16. De Luca G, Valgimigli M, Spaulding C, et al. Short and long-term benefits of sirolimus-eluting stent in ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. J Thromb Thrombolysis. 2009;28(2):200-210.
17. Dibra A, Tiroch K, Schulz S, et al. Drug-eluting stents in acute myocardial infarction: updated meta-analysis of randomized trials. Clin Res Cardiol. 2010;99(6):345-357.
18. McFadden EP, Stabile E, Regar E, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet. 2004;364(9444):1519-1521. (Pubitemid 39410418)
19. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents. JAMA. 2005;293(17):2126-2130. (Pubitemid 40617065)
20. Spertus JA, Kettelkamp R, Vance C, et al. Prevalence, predictors, and outcomes of premature discontinuation of thienopyridine therapy after drugeluting stent placement: results from the PREMIER registry. Circulation. 2006;113(24):2803-2809. (Pubitemid 44305292)
21. Kernis SJ, Cohen D, Rein K. Clinical outcome associated with use of drug-eluting stents compared with bare metal stent for primary percutaneous intervention [abstract]. Am J Cardiol. 2005;96(suppl 7A):47H.
22. Daemen J, Tanimoto S, García-García HM, et al. Comparison of three-year clinical outcome of sirolimus- and paclitaxel-eluting stents versus bare metal stents in patients with ST-segment elevation myocardial infarction (from the RESEARCH and T-SEARCH Registries). Am J Cardiol. 2007;99(8):1027-1032. (Pubitemid 46560473)
23. Egger M, Smith GD. Bias in location and selection of studies. BMJ. 1998;316(7124):61-66.
24. Cortese G, Scheike TH,Martinussen T. Flexible survival regression modelling. Stat Methods Med Res. 2010;19(1):5-28.
25. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of metaanalyses of randomised controlled trials: the QUOROM statement: quality of reporting of meta-analyses. Lancet. 1999;354(9193):1896- 1900.
26. Pasceri V, Granatelli A, Pristipino C. A randomized trial of a rapamycin-eluting stent in acute myocardial infarction: preliminary results [abstract]. Am J Cardiol. 2003;92(suppl 6A):1L.
27. Pittl U, Kaiser C, Brunner-La Rocca HP; BASKET Investigators. Safety and efficacy of drug eluting stents vs bare metal stents in primary angioplasty of patients with acute ST-elevation myocardial infarction - a prospective randomized study [abstract]. Eur Heart J. 2006;27(abstract suppl):650.
28. Sardella G, Paroli M, Mancone M. Impact of paclitaxel- eluting stent implantation in patients with STEMI on anti-inflammatory IL-10-producing T regulatory 1 (Tr1) cells [abstract]. Eur Heart J. 2006;27(abstract suppl):831.
29. Tierala I. Helsinki Area Acute Myocardial Infarction Treatment Re-Evaluation - should the patient get a drug-eluting or a normal stent (HAAMU-STENT) study. http://www.tctmd.com/show.aspx?id=398&ref-id=48792. Accessed May 2011.
30. Chechi T, Vittori G, Biondi Zoccai GG, et al. Single-center randomized evaluation of paclitaxel-eluting versus conventional stent in acute myocardial infarction (SELECTION). J Interv Cardiol. 2007;20(4):282-291. (Pubitemid 47228553)
31. Karjalainen P. TITAX AMI Trial. http://www.slideshare.net/benklinger/ titax-tct-2007. Accessed May 2011.
32. Díaz de la Llera LS, Ballesteros S, Nevado J, et al. Sirolimus-eluting stents compared with standard stents in the treatment of patients with primary angioplasty. Am Heart J. 2007;154(1):164.e1-164.e6.
33. Di Lorenzo E, Sauro R, Varricchio A, et al. Benefits of drug-eluting stents as compared to bare metal stent in ST-segment elevation myocardial infarction: four year results of the PaclitAxel or Sirolimus- Eluting stent vs bare metal stent in primary angiOplasty (PASEO) randomized trial. Am Heart J. 2009;158(4):e43-e50.
34. Tebaldi M, Arcozzi C, Campo G, Percoco G, Ferrari R, Valgimigli M; STRATEGY Investigators. The 5-year clinical outcomes after a randomized comparison of sirolimus-eluting versus baremetal stent implantation in patients with ST-segment elevation myocardial infarction. J Am Coll Cardiol. 2009;54(20):1900-1901.
35. Violini R, Musto C, De Felice F, et al. Maintenance of long-term clinical benefit with sirolimus-eluting stents in patients with ST-segment elevation myocardial infarction 3-year results of the SESAMI (sirolimus-eluting stent versus baremetal stent in acute myocardial infarction) trial. J Am Coll Cardiol. 2010;55(8):810-814.
36. Kaltoft A, Kelbaek H, Thuesen L, et al. Long-term outcome after drug-eluting versus bare-metal stent implantation in patients with ST-segment elevation myocardial infarction: 3-year follow-up of the randomized DEDICATION (Drug Elution and Distal Protection in Acute Myocardial Infarction) Trial. J Am Coll Cardiol. 2010;56(8):641-645.
37. Atary JZ, van der Hoeven BL, Liem SS, et al. Three-year outcome of sirolimus-eluting versus bare-metal stents for the treatment of ST-segment elevation myocardial infarction (from the MISSION! Intervention Study). Am J Cardiol. 2010;106(1):4-12.
38. Vink MA, Dirksen MT, Suttorp MJ, et al. 5-year follow-up after primary percutaneous coronary intervention with a paclitaxel-eluting stent versus a bare-metal stent in acute ST-segment elevation myocardial infarction: a follow-up study of the PASSION (Paclitaxel-Eluting Versus Conventional Stent in Myocardial Infarction with ST-Segment Elevation) trial. JACC Cardiovasc Interv. 2011;4(1):24-29.
39. Spaulding C, Teiger E, Commeau P, et al. Four-year follow-up of TYPHOON (trial to assess the use of the CYPHer sirolimus-eluting coronary stent in acute myocardial infarction treated with BallOON angioplasty). JACC Cardiovasc Interv. 2011;4(1):14-23.
40. Valgimigli M, Campo G, Gambetti S, et al; MULTIcentre evaluation of Single high-dose bolus TiRofiban vs Abciximab with sirolimus eluting sTEnt or Bare Metal Stent in Acute Myocardial Infarction studY (MULTISTRATEGY) investigators. Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY) [published online August 24, 2011]. Int J Cardiol. doi:10.1016/j.ijcard.2011.07.106.
41. George BS, Voorhees WD III, Roubin GS, et al. Multicenter investigation of coronary stenting to treat acute or threatened closure after percutaneous transluminal coronary angioplasty: clinical and angiographic outcomes. J Am Coll Cardiol. 1993;22(1):135-143. (Pubitemid 23189946)
42. Schömig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med. 1996;334(17):1084-1089. (Pubitemid 26120185)
43. EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade. Lancet. 1998;352(9122):87-92.
44. Suryapranata H, van 't Hof AW, Hoorntje JC, de Boer MJ, Zijlstra F. Randomized comparison of coronary stenting with balloon angioplasty in selected patients with acute myocardial infarction. Circulation. 1998;97(25):2502-2505. (Pubitemid 28294495)
45. Antoniucci D, Santoro GM, Bolognese L, Valenti R, Trapani M, Fazzini PF. A clinical trial comparing primary stenting of the infarct-related artery with optimal primary angioplasty for acute myocardial infarction: results from the Florence Randomized Elective Stenting in Acute Coronary Occlusions (FRESCO) trial. J Am Coll Cardiol. 1998;31(6):1234-1239.
46. Grines CL, Cox DA, Stone GW, et al Stent Primary Angioplasty in Myocardial Infarction Study Group. Coronary angioplasty with or without stent implantation for acute myocardial infarction. N Engl J Med. 1999;341(26):1949- 1956. (Pubitemid 30010402)
47. Gibson CM, Karha J, Murphy SA, et al TIMI Study Group. Early and long-term clinical outcomes associated with reinfarction following fibrinolytic administration in the Thrombolysis in Myocardial Infarction trials. J Am Coll Cardiol. 2003;42(1):7-16. (Pubitemid 36760755)
48. De Luca G, Ernst N, van 't Hof AW, et al. Predictors and clinical implications of early reinfarction after primary angioplasty for ST-segment elevation myocardial infarction. Am Heart J. 2006;151(6):1256-1259. (Pubitemid 43866607)
49. Stettler C, Wandel S, Allemann S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007;370(9591):937-948. (Pubitemid 47393576)
50. Hakeem A, Helmy T, Munsif S, et al. Safety and efficacy of drug eluting stents compared with bare metal stents for saphenous vein graft interventions: a comprehensive meta-analysis of randomized trials and observational studies comprising 7,994 patients. Catheter Cardiovasc Interv. 2011;77(3):343-355.
51. Cortese B, Bertoletti A, De Matteis S, Danzi GB, Kastrati A. Drug-eluting stents perform better than bare metal stents in small coronary vessels: a meta-analysis of randomised and observational clinical studies with mid-term follow up [published online May 13, 2011]. Int J Cardiol. doi:10.1016/j.ijcard. 2011.04.016.
52. Ma J, Yang W, Singh M, Peng T, Fang N, Wei M. Meta-analysisoflong- termoutcomesofdrug-eluting stent implantations for chronic total coronary occlusions. Heart Lung. 2011;40(3):e32-e40.
53. Piccolo R, Cassese S, Galasso G, De Rosa R, D'Anna C, Piscione F. Long-term safety and efficacy of drug-eluting stents in patients with acute myocardial infarction: ameta-analysis of randomized trials. Atherosclerosis. 2011;217(1):149-157.
54. Wallace EL, Abdel-Latif A, Charnigo R, Moliterno DJ, Brodie B,MatnaniR, Ziada KM. Meta-analysis of long-term outcomes for drug-eluting stents versus bare-metal stents in primary percutaneous coronary interventions for ST-segment elevation myocardial infarction [published online January 3, 2012]. Am J Cardiol. doi:10.1016/j.amjcard.2011.11.021.
55. Stone GW, Ellis SG, Colombo A, et al. Long-term safety and efficacy of paclitaxel-eluting stents final 5-year analysis from the TAXUS Clinical Trial Program. JACC Cardiovasc Interv. 2011;4(5):530-542.
56. Stone GW, Ellis SG, Colombo A, et al. Offsetting impact of thrombosis and restenosis on the occurrence of death and myocardial infarction after paclitaxel-eluting and bare metal stent implantation. Circulation. 2007;115(22):2842-2847. (Pubitemid 46869671)
57. Kereiakes DJ, Smits PC, Kedhi E, et al. Predictors of death or myocardial infarction, ischaemic-driven revascularisation, and major adverse cardiovascular events following everolimus-eluting or paclitaxel-eluting stent deployment: pooled analysis from the SPIRIT II, III, IV and COMPARE trials. EuroIntervention. 2011;7(1):74-83.
58. Kimura T, Morimoto T, Kozuma K, et al RESTART Investigators. Comparisons of baseline demographics, clinical presentation, and long-term outcome among patients with early, late, and very late stent thrombosis of sirolimus-eluting stents: observations from the Registry of Stent Thrombosis for Review and Reevaluation (RESTART). Circulation. 2010;122(1):52-61.
59. Windecker S, Serruys PW, Wandel S, et al. Biolimus- eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomised non-inferiority trial. Lancet. 2008;372(9644):1163-1173.
60. Navarese EP, Kubica J, Castriota F, et al. Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a metaanalysis of randomised trials. EuroIntervention. 2011;7(8):985-994.
61. Wallentin L, Becker RC, Budaj A, et al PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361(11):1045-1057.
62. Wiviott SD, Braunwald E, McCabe CH, et al TRITON-TIMI 38 Investigators. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2007;357(20):2001-2015. (Pubitemid 350106708)